[The efficacy of antiviral therapy and drug resistance analysis among HIV/AIDS patients with heroin addiction in Guangxi Zhuang Autonomous Region].
PMID: 25573121
2014
Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]
Abstract: Among the patients who received antiviral treatment, the mutation frequency of M184V/I, T215Y/F, L210W and T69N/S in heroin abuser group were significantly higher than that in never using drug group (14.9% (11/74) vs 4.4% (3/68), 12.2% (9/74) vs 1.5% (1/68), 12.2% (9/74) vs 1.5% (1/68) and 10.8% (8/74) vs 1.5% (1/68) respectively) (P < 0.05).
Persistence of frequently transmitted drug-resistant HIV-1 variants can be explained by high viral replication capacity.
Method: The RC of either the SDM-viruses or the patient-derived viruses was compared to the RC of control viruses (WT, HIV-M184V, -M184I and -M184T).
Result: The RC of p46I an
Result: The difference in RC between HIV-WT, -M184V and -M184I has been demonstrated to be biologically relevant in vivo.
Figure: In all experiments, control viruses HIV-M184V, -M184I and -M184T and wild type (WT) HIV were used as reference viruses.
Discussion: In our patients, the vast majority of TDRM persisted for at least a year and up to eight years, confirming observations from previous studies that except for M184V/I, TDRM generally persist for longer than one year.
Cobicistat-boosted darunavir in HIV-1-infected adults: week 48 results of a Phase IIIb, open-label single-arm trial.
Method: For any patients with the M184V/I RAM present at screening, emtricitabine or lamivudine could be included as a third (not fully active) N[t]RTI for the purpose of maintaining M184V/I.
Result: N[t]RTI RAMs were found in 14% of patients (43/313; 36 and seven patients), most commonly V118I (6%; 18/313; 18 and zero patients), T69D/N (3%; 8/313; eight and zero patients) and M184V/I (3%; 8/313; two and six patients).
Rilpivirine resistance mutations in HIV patients failing non-nucleoside reverse transcriptase inhibitor-based therapies.
High rate of antiretroviral drug resistance mutations in HIV type 1-infected Senegalese children in virological failure on first-line treatment according to the World Health Organization guidelines.
PMID: 22860571
2013
AIDS research and human retroviruses
Abstract: The NRTI-resistant viruses harbored the M184V/I (95%), Q151M (2%), and thymidine-analogue mutations (40%), and the NNRTI-resistant viruses harbored the K103N (34%), Y181C (32%), G190A (23%), and K101E (21%) mutations.
Tenofovir-based regimens associated with less drug resistance in HIV-1-infected Nigerians failing first-line antiretroviral therapy.
Abstract: 90% had the M184V/I mutation, 62% had at least one thymidine analog mutation, and 14% had the K65R mutation.
Result: Most (90%) patients harbored the M184V/I mutation and 14% had the K65R mutation.
Result: Patients on TDF based regimens were significantly more likely to have thymidine-sparing mutations (K65R (57%), Discussion: M184I (7/23) and Y115F (3/23), are relatively uncommon mutations but occurred more often for those on tenofovir.
Discussion: The M184I may eventually switch to M184V and Y115F may be increasing for those on tenofovir, but the small numbers limit our inferences.
From the chemistry of epoxy-sugar nucleosides to the discovery of anti-HIV agent 4'-ethynylstavudine-Festinavir.
Introduction: The N348I mutation was reported to be highly correlated with the M184V/I mutation.
HIV-2 antiviral potency and selection of drug resistance mutations by the integrase strand transfer inhibitor elvitegravir and NRTIs emtricitabine and tenofovir in vitro.
PMID: 23187937
2013
Journal of acquired immune deficiency syndromes (1999)
Abstract: In resistance selections, EVG selected E92G/Q and S147N in integrase, FTC selected M184V/I in RT, and TFV selected K65R and Y115F in RT.
Abstract: The RT M184I and M184V SDM viruses were both highly resistant to FTC (34- and >1000-fold, respectively).
Greater suppression of nevirapine resistance with 21- vs 7-day antiretroviral regimens after intrapartum single-dose nevirapine for prevention of mother-to-child transmission of HIV.
HIV mutation literature information.
PMID: 
2014
Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]
Browser Board
Co-occurred Entities
Filtrator
ViMRT